Skip to main content

Table 3 Medication use at enrollment by the patients enrolled in the CARRA Registry in the first 12 months of operation

From: The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months

Medication Number (%) of Current Users Number (%) of Ever Users
Methotrexate 556 (47%) 868 (73%)
Leflunomide 52 (4%) 71 (6%)
Sulfasalazine 20 (2%) 49 (4%)
Hydroxychloroquine 49 (4%) 69 (6%)
Adalimumab 140 (12%) 235 (20%)
Etanercept 273 (23%) 505 (42%)
Golimumab 7 (1%) 13 (1%)
Infliximab 44 (4%) 95 (8%)
Any TNFi 465 (39%) 664 (56%)
Any TNFi + Methotrexate 255 (21%) n/a
Abatacept 17 (1%) 55 (5%)
Tocilizumab 59 (5%) 115 (10%)
Tocilizumab + Methotrexate 42 (4%) n/a
Anakinra 24 (2%) 75 (6%)
Canakinumab 29 (2%) 46 (4%)
Any IL-1 inhibitor + Methotrexate 18 (2%) n/a
Rituximab 3 (<1%) 16 (1%)
Oral glucocorticoids 124 (10%) 560 (47%)
  1. TNFi tumor necrosis factor inhibitor, IL-1 interleukin 1, n/a not assessed